Loading company…
Clinical-stage biopharma developing small-molecule treatments for NASH and other chronic liver diseases.
Terns Pharmaceuticals, Inc. was founded in 2017 and is based in Foster City, California, US, with Senthil Sundaram as CEO. The company is developing TERN-101, a liver-distributed, non-steroidal FXR agonist, for non-alcoholic steatohepatitis and other chronic liver diseases. It has raised a total of USD 197 million over 3 funding rounds. In February 2021 it priced an upsized IPO of USD 127.5 million, selling 7.5 million shares at USD 17 per share on NASDAQ.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in